As it has been well established, breast cancer is the so-called “cold tumor” that with the paucity of tumor T-cell infiltration, we suggest ICOS agonist mAbs might be of promising to promote the anti-tumor T-cell responses. This evidence concerns the gene ICOS and breast carcinoma.